Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

March 12, 2025 07:00 ET | Source: Bavarian Nordic A/S

Bavarian Nordic A/S - Indkaldelse til ordinær generalforsamling

KØBENHAVN, Danmark, 12. marts 2025 – I overensstemmelse med vedtægternes §§ 10-14 indkaldes herved til ordinær generalforsamling i Bavarian Nordic A/S: Onsdag den 9. april 2025 kl. 16.00 hos Comwell...
March 12, 2025 07:00 ET | Source: Bavarian Nordic A/S

Bavarian Nordic A/S – Notice Convening Annual General Meeting

COPENHAGEN, Denmark, March 12, 2025 – Pursuant to Articles 10-14 of the Articles of Association, the shareholders of Bavarian Nordic A/S are hereby convened to the Annual General Meeting to be held on...
March 07, 2025 01:30 ET | Source: Bavarian Nordic A/S

Bavarian Nordics ansøgning om markedsføringstilladelse for chikungunyavaccinen for personer i alderen 12 år og ældre er blevet accepteret af de britiske lægemiddelmyndigheder

KØBENHAVN, Danmark, 7. marts 2025 – Bavarian Nordic A/S (OMX: BAVA) offentliggjorde i dag, at de britiske lægemiddelmyndigheder, UK Medicines and Healthcare products Regulatory Agency (MHRA), har...
March 07, 2025 01:30 ET | Source: Bavarian Nordic A/S

Bavarian Nordic Announces Acceptance of Marketing Authorization Application for Chikungunya Vaccine in the UK for Persons Aged 12 and Older

COPENHAGEN, Denmark, March 7, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has validated the marketing authorization...
March 05, 2025 02:08 ET | Source: Bavarian Nordic A/S

Indberetning af ledende medarbejdere og disses nærtståendes transaktioner med Bavarian Nordic aktier og tilknyttede værdipapirer

KØBENHAVN, Danmark, 5. marts 2025 – Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om følgende transaktioner med selskabets aktie/tilknyttede værdipapirer, foretaget af ledende...
March 05, 2025 02:08 ET | Source: Bavarian Nordic A/S

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, March 5, 2025 – Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the Company’s shares/related securities by persons holding...
March 05, 2025 01:50 ET | Source: Bavarian Nordic A/S

Bavarian Nordic offentliggør årsrapport for 2024

De reviderede resultater bekræfter en omsætning for helåret på DKK 5.716 mio. og et resultat af primær drift før afskrivninger og nedskrivninger (EBITDA) på DKK 1.603 mio.To nye tidlig-fase...
March 05, 2025 01:50 ET | Source: Bavarian Nordic A/S

Bavarian Nordic Publishes Annual Report 2024

Audited results confirm full-year revenue of DKK 5,716 million and EBITDA of DKK 1,603 million.Two new early-stage pipeline programs, Lyme disease and Epstein-Barr Virus (EBV), introduced. ...
February 28, 2025 11:14 ET | Source: Bavarian Nordic A/S

Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

First chikungunya vaccine approved in Europe for persons as young as 12 years old.On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, February 28, 2025 –...
February 28, 2025 11:14 ET | Source: Bavarian Nordic A/S

Bavarian Nordic Receives Marketing Authorization in Europe for Chikungunya Vaccine for Persons Aged 12 and Older

First chikungunya vaccine approved in Europe for persons as young as 12 years old.On track for launch in key European markets in the first half of 2025. COPENHAGEN, Denmark, February 28, 2025 –...